You are here

Cardiovascular Disease Management

Managing patients with cardiovascular disease (CVD) goes beyond treating their symptoms; it involves the ongoing management of their condition in order to help reduce the risk of potentially fatal events.

Consider that atrial fibrillation (AF) is associated with 5-fold increase in the risk of strokes.1 Similarly, within 3 months of hospitalization for deep vein thrombosis (DVT) or pulmonary embolism (PE), two-thirds of recurrent events occurred in the first month postdischarge.2 Among study patients who stopped taking prescribed anticoagulants, 29.1% experienced a recurrent VTE at 5 years, while 12% of all recurrent VTEs resulted in a fatal event.3

The tools and resources available through the Janssen CarePath Healthy Engagements program can help inform your patients about cardiovascular conditions. Effective management can help reduce the risk of cardiovascular events such as DVT and PE. You will also find additional resources designed to support improved care coordination among healthcare professionals to engage and align efforts around improving quality of care, transitions of care, and ultimately, patient outcomes. 

View resources designed to activate patients to be engaged in the care management of CVD.

Explore resources designed to support improved care coordination efforts among providers and enhance communication between providers and patients.

Janssen tools and resources have not been proven to improve outcomes and may not completely address the specific intervention activities listed on each page. Janssen tools or resources discussed should be evaluated against other available sources of information before decisions are made about how to approach patient care within your organization. Full descriptions of appropriate use and associated limitations are set forth in the respective tools and resources.

This information has been developed by Janssen Pharmaceuticals, Inc., and made widely available to support patient and provider education.

References:

  1. Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
  2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
  3. Miller S. MAP: bad Rx decisions cost poor US states most. lab.express-scripts.com/insights/drug-options/map-bad-rx-decisions-cost-poor-us-states. Accessed December 14, 2017.
  4. García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175-194.
  5. Hernandez-Tejada MA, Campbell JA, Walker RJ, Smalls BL, Davis KS, Egede LE. Diabetes empowerment, medication adherence and self-care behaviors in adults with type 2 diabetes. Diabetes Technol Ther. 2012;14(7):630-634.

Click here to browse the full library of available resources.